(MedPage Today) — The FDA approved acalabrutinib (Calquence) plus venetoclax (Venclexta) for previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma as the first all-oral, fixed-duration regimen in the frontline setting…
Source link : https://www.medpagetoday.com/hematologyoncology/leukemia/119970
Author :
Publish date : 2026-02-20 17:14:00
Copyright for syndicated content belongs to the linked Source.
